Panitumumab to prevent the progression of eyeball elongation in adults with nearsightedness and macular degeneratio
Phase 1
- Conditions
- Eye DiseasesAdult highly myopic patients with myopic macular degeneration
- Registration Number
- ISRCTN96896687
- Lead Sponsor
- fa Eye Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
1. Aged <50 years old
2. Axial length >26.0 mm
3. Myopic macular degeneration of stage 4 (foveal patchy atrophy)
4. Best corrected visual acuity >1.0 logMAR (logarithm of the minimal angle of resolution) (20/200 Snellen equivalent)
Exclusion Criteria
Not meeting the inclusion criteria
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Intraocular safety, defined by signs of intraocular inflammation, such as cells in the aqueous humour, increased Tyndall phenomenon, cells in the vitreous body, intraocular pressure, measured by slit lamp biomicroscopy of the anterior and posterior segment of the eye and applanation tonometry, at baseline and at every re-examination, i.e., at day 1 and 7 and at one and two months after each injection to search for signs of acute inflammation
- Secondary Outcome Measures
Name Time Method Axial length, measured by laser interferometric biometry at baseline, at every re-injection, and at the study end at 6 months